Association of Non-selective β Blockers with the Development of Renal Dysfunction in Liver Cirrhosis: a Systematic Review and Meta-analysis

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Jan 25

PMID 38271554

Authors

Xiangbo Xu

Fangbo Gao

Ting Wang

Zuyao Yang

Qingchun Zhao

Xingshun Qi

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Non-selective β blockers (NSBBs) may negatively influence renal function through decreasing heart rate and cardiac output. This study aimed to systematically investigate their association.

Methods: PubMed, EMBASE, and Cochrane library databases were searched to identify all relevant studies evaluating the association of NSBBs with renal dysfunction in cirrhotic patients. Unadjusted and adjusted data were separately extracted. Odds ratios (ORs) and hazard ratios (HRs) were pooled. Subgroup meta-analyses were performed according to the proportions of ascites and Child-Pugh class B/C and the mean model for end-stage liver disease (MELD) score. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.

Results: Fourteen studies were finally included. Based on unadjusted data, NSBBs significantly increased the risk of developing renal dysfunction (OR = 1.49; = 0.03), and this association remained significant in subgroup analyses of studies where the proportions of ascites was >70% and Child-Pugh class B/C was 100%. Based on adjusted data with propensity score matching (adjusted OR = 0.61; = 0.08) and multivariable regression modelling (adjusted HR = 0.86; = 0.713), NSBBs did not increase the risk of developing renal dysfunction, and this association remained not significant in subgroup analyses of studies where the proportions of ascites was >70% and <70%, the proportion of Child-Pugh class B/C was <100%, and the mean MELD score was <15. The quality of evidence was very low for all meta-analyses.

Conclusions: NSBBs may not be associated with the development of renal dysfunction in liver cirrhosis. However, more evidence is required to clarify their association in specific populations.

References

Turco L, Villanueva C, La Mura V, Garcia-Pagan J, Reiberger T, Genesca J . Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clin Gastroenterol Hepatol. 2019; 18(2):313-327.e6. DOI: 10.1016/j.cgh.2019.05.050. View

Xu X, Guo X, De Stefano V, Silva-Junior G, Goyal H, Bai Z . Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int. 2019; 13(4):468-481. DOI: 10.1007/s12072-019-09951-6. View

Facciorusso A, Roy S, Livadas S, Fevrier-Paul A, Wekesa C, Dogu Kilic I . Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. Dig Dis Sci. 2018; 63(7):1737-1746. DOI: 10.1007/s10620-018-5092-6. View

Kim S, Larson J, Lee J, Therneau T, Kim W . Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017; 23(6):733-740. PMC: 5449204. DOI: 10.1002/lt.24744. View

Maiwall R, Pasupuleti S, Jain P, Sarin S . Degree of Portal and Systemic Hemodynamic Alterations Predict Recurrent AKI and Chronic Kidney Disease in Patients With Cirrhosis. Hepatol Commun. 2021; 5(2):293-308. PMC: 7850308. DOI: 10.1002/hep4.1607. View

Tariq R, Singal A . Management of Hepatorenal Syndrome: A Review. J Clin Transl Hepatol. 2020; 8(2):192-199. PMC: 7438356. DOI: 10.14218/JCTH.2020.00011. View

Kumar M, Kainth S, Choudhury A, Maiwall R, Mitra L, Saluja V . Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. 2019; 13(6):800-813. DOI: 10.1007/s12072-019-09986-9. View

Li T, Liu C, Huang C, Tsai Y, Huang S, Yang Y . Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study. J Clin Med. 2021; 10(11). PMC: 8196849. DOI: 10.3390/jcm10112244. View

Campbell M, Kotlyar D, Brensinger C, Lewis J, Shetty K, Bloom R . Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl. 2005; 11(9):1048-55. DOI: 10.1002/lt.20445. View

10.

Ngwa T, Orman E, Vilar Gomez E, Vuppalanchi R, Kubal C, Chalasani N . Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. BMC Gastroenterol. 2020; 20(1):4. PMC: 6945622. DOI: 10.1186/s12876-019-1155-1. View

11.

Ruiz-Del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A . Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003; 38(5):1210-8. DOI: 10.1053/jhep.2003.50447. View

12.

Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P . Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology. 2015; 63(6):1968-76. DOI: 10.1002/hep.28352. View

13.

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

14.

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

15.

Garcia-Tsao G, Parikh C, Viola A . Acute kidney injury in cirrhosis. Hepatology. 2008; 48(6):2064-77. DOI: 10.1002/hep.22605. View

16.

Krag A, Bendtsen F, Burroughs A, Moller S . The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012; 79(1):53-5. DOI: 10.1016/j.mehy.2012.03.032. View

17.

Sasso R, Rockey D . Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection. Aliment Pharmacol Ther. 2020; 53(3):418-425. DOI: 10.1111/apt.16156. View

18.

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

19.

. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; 69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024. View

20.

Bhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, OLeary J . Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2017; 47(1):78-85. PMC: 6016372. DOI: 10.1111/apt.14366. View